Laura Chico
Stock Analyst at Wedbush
(3.63)
# 806
Out of 5,072 analysts
228
Total ratings
46.2%
Success rate
6.89%
Average return
Main Sectors:
Stocks Rated by Laura Chico
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PHVS Pharvaris | Maintains: Outperform | $27 → $30 | $25.45 | +17.88% | 8 | Nov 13, 2025 | |
| MAZE Maze Therapeutics | Maintains: Outperform | $35 → $36 | $36.67 | -1.83% | 2 | Nov 7, 2025 | |
| EWTX Edgewise Therapeutics | Maintains: Outperform | $35 → $32 | $24.06 | +33.00% | 11 | Nov 7, 2025 | |
| DNTH Dianthus Therapeutics | Maintains: Outperform | $44 → $46 | $44.09 | +4.33% | 10 | Nov 6, 2025 | |
| PRAX Praxis Precision Medicines | Maintains: Underperform | $73 → $77 | $184.25 | -58.21% | 8 | Nov 6, 2025 | |
| STOK Stoke Therapeutics | Maintains: Outperform | $22 → $32 | $29.82 | +7.31% | 8 | Nov 5, 2025 | |
| ATXS Astria Therapeutics | Downgrades: Neutral | $28 → $13 | $12.34 | +5.35% | 10 | Oct 15, 2025 | |
| LRMR Larimar Therapeutics | Maintains: Outperform | $15 → $11 | $3.67 | +199.73% | 3 | Sep 30, 2025 | |
| PEPG PepGen | Maintains: Outperform | $9 → $8 | $6.05 | +32.23% | 12 | Sep 30, 2025 | |
| JBIO Jade Biosciences | Maintains: Outperform | $17 → $18 | $12.54 | +43.54% | 3 | Aug 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $17 → $14 | $5.15 | +171.84% | 3 | Aug 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $42 → $43 | $43.94 | -2.14% | 9 | Aug 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $32 | $36.01 | -11.14% | 12 | Aug 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $4 → $5 | $3.27 | +52.91% | 6 | Aug 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $13 → $14 | $5.72 | +144.76% | 14 | Aug 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $137 → $141 | $143.53 | -1.76% | 10 | Jul 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $35 → $34 | $33.53 | +1.42% | 13 | Jul 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $16 → $18 | $6.85 | +162.77% | 1 | Jun 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $130 | $131.08 | -0.82% | 1 | Jun 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $121 | $181.96 | -33.50% | 18 | Jun 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $4 | $13.36 | -70.06% | 4 | May 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $32 → $30 | $19.13 | +56.82% | 8 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $34 → $26 | $29.43 | -11.65% | 8 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $4 → $3 | $1.50 | +100.00% | 2 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $30 → $29 | $21.00 | +38.10% | 14 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $8 → $7 | $3.97 | +76.32% | 4 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $42 | $31.41 | +33.72% | 7 | Jul 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $13 → $11 | $0.65 | +1,594.39% | 4 | Apr 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $5 | $9.41 | -46.87% | 5 | Mar 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | n/a | $56.29 | - | 5 | Sep 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $9 → $5 | $4.59 | +8.93% | 2 | Aug 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $149 | $9.41 | +1,478.11% | 1 | Aug 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $720 | $11.37 | +6,232.45% | 1 | Jan 19, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Strong Buy | $280 | $219.65 | +27.48% | 1 | Apr 21, 2017 |
Pharvaris
Nov 13, 2025
Maintains: Outperform
Price Target: $27 → $30
Current: $25.45
Upside: +17.88%
Maze Therapeutics
Nov 7, 2025
Maintains: Outperform
Price Target: $35 → $36
Current: $36.67
Upside: -1.83%
Edgewise Therapeutics
Nov 7, 2025
Maintains: Outperform
Price Target: $35 → $32
Current: $24.06
Upside: +33.00%
Dianthus Therapeutics
Nov 6, 2025
Maintains: Outperform
Price Target: $44 → $46
Current: $44.09
Upside: +4.33%
Praxis Precision Medicines
Nov 6, 2025
Maintains: Underperform
Price Target: $73 → $77
Current: $184.25
Upside: -58.21%
Stoke Therapeutics
Nov 5, 2025
Maintains: Outperform
Price Target: $22 → $32
Current: $29.82
Upside: +7.31%
Astria Therapeutics
Oct 15, 2025
Downgrades: Neutral
Price Target: $28 → $13
Current: $12.34
Upside: +5.35%
Larimar Therapeutics
Sep 30, 2025
Maintains: Outperform
Price Target: $15 → $11
Current: $3.67
Upside: +199.73%
PepGen
Sep 30, 2025
Maintains: Outperform
Price Target: $9 → $8
Current: $6.05
Upside: +32.23%
Jade Biosciences
Aug 14, 2025
Maintains: Outperform
Price Target: $17 → $18
Current: $12.54
Upside: +43.54%
Aug 13, 2025
Maintains: Outperform
Price Target: $17 → $14
Current: $5.15
Upside: +171.84%
Aug 12, 2025
Maintains: Outperform
Price Target: $42 → $43
Current: $43.94
Upside: -2.14%
Aug 7, 2025
Maintains: Outperform
Price Target: $30 → $32
Current: $36.01
Upside: -11.14%
Aug 6, 2025
Maintains: Outperform
Price Target: $4 → $5
Current: $3.27
Upside: +52.91%
Aug 5, 2025
Maintains: Outperform
Price Target: $13 → $14
Current: $5.72
Upside: +144.76%
Jul 31, 2025
Maintains: Outperform
Price Target: $137 → $141
Current: $143.53
Upside: -1.76%
Jul 14, 2025
Maintains: Neutral
Price Target: $35 → $34
Current: $33.53
Upside: +1.42%
Jun 30, 2025
Maintains: Outperform
Price Target: $16 → $18
Current: $6.85
Upside: +162.77%
Jun 18, 2025
Reiterates: Neutral
Price Target: $130
Current: $131.08
Upside: -0.82%
Jun 12, 2025
Reiterates: Neutral
Price Target: $121
Current: $181.96
Upside: -33.50%
May 15, 2025
Reiterates: Neutral
Price Target: $4
Current: $13.36
Upside: -70.06%
May 7, 2025
Maintains: Outperform
Price Target: $32 → $30
Current: $19.13
Upside: +56.82%
May 7, 2025
Maintains: Neutral
Price Target: $34 → $26
Current: $29.43
Upside: -11.65%
Mar 12, 2025
Maintains: Outperform
Price Target: $4 → $3
Current: $1.50
Upside: +100.00%
Mar 3, 2025
Maintains: Neutral
Price Target: $30 → $29
Current: $21.00
Upside: +38.10%
Aug 7, 2024
Maintains: Neutral
Price Target: $8 → $7
Current: $3.97
Upside: +76.32%
Jul 29, 2024
Reiterates: Outperform
Price Target: $42
Current: $31.41
Upside: +33.72%
Apr 11, 2024
Maintains: Outperform
Price Target: $13 → $11
Current: $0.65
Upside: +1,594.39%
Mar 20, 2024
Reiterates: Neutral
Price Target: $5
Current: $9.41
Upside: -46.87%
Sep 28, 2023
Initiates: Market Perform
Price Target: n/a
Current: $56.29
Upside: -
Aug 12, 2022
Maintains: Outperform
Price Target: $9 → $5
Current: $4.59
Upside: +8.93%
Aug 8, 2022
Downgrades: Neutral
Price Target: $149
Current: $9.41
Upside: +1,478.11%
Jan 19, 2018
Initiates: Outperform
Price Target: $720
Current: $11.37
Upside: +6,232.45%
Apr 21, 2017
Initiates: Strong Buy
Price Target: $280
Current: $219.65
Upside: +27.48%